Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai has been highly commended for its initiatives to promote access to medicines and ranked 11th among the world’s leading pharmaceutical companies in the Access to Medicine Index (ATM Index) 2016.
This Index is compiled by the Access to Medicine Foundation (the Foundation), an international non-profit organization dedicated to improving access to medicine for patients in need. Based on publicly disclosed information and individual surveys, the ATM Index independently evaluates companies’ efforts to improve access to medicine for diseases and countries designated by the Index to rank the world’s top 20 pharmaceutical companies leading in initiatives for access to medicine issues in developing and emerging countries. The ATM Index has been published by the Foundation every two years since 2008.
Eisai performed above the Index average in the following four technical areas set by the Foundation: general access to medicine management, market influence & compliance, research & development, as well as product donations.
In the ATM Index 2016 report, Eisai’s commitment to eliminating lymphatic filariasis, a neglected tropical disease, by providing 2.2 billion diethylcarbamazine citrate (DEC) tablets free of charge to endemic countries in collaboration with the World Health Organization (WHO) for a seven year period starting from 2013, was highly commended. In addition, the Foundation highlighted as best practices Eisai’s strategies for using partnerships to accelerate research and development of new treatments for conditions including neglected tropical diseases (NTDs), malaria and tuberculosis, as well as its initiatives to create patient value with all employees around the world using 1% of their total business hours to interact with patients.
Eisai is establishing proactive partnerships with various stakeholders including governments, international organizations and other non-profit private sector organizations to improve access to medicines worldwide under its human health care (hhc) philosophy. Together with accelerating the development of new medicines for infectious diseases endemic in developing and emerging countries through these partnerships, the Eisai Group is committed to additional long-term sustainable strategies including raising disease awareness locally and implementing price setting models that take income levels into account for greater access to medicine worldwide.
Please click the following link for details of the ATM Index 2016 results: